JP2011528666A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528666A5 JP2011528666A5 JP2011518947A JP2011518947A JP2011528666A5 JP 2011528666 A5 JP2011528666 A5 JP 2011528666A5 JP 2011518947 A JP2011518947 A JP 2011518947A JP 2011518947 A JP2011518947 A JP 2011518947A JP 2011528666 A5 JP2011528666 A5 JP 2011528666A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- retigabine
- pharmaceutical
- binder
- disease characterized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229960003312 retigabine Drugs 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 4
- 206010001497 Agitation Diseases 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 210000000653 nervous system Anatomy 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 108091006146 Channels Proteins 0.000 claims 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 239000003945 anionic surfactant Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 238000012377 drug delivery Methods 0.000 claims 2
- WAALZLLYFVFZTQ-UHFFFAOYSA-N ethyl n-[2-amino-4-[benzyl(fluoro)amino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1N(F)CC1=CC=CC=C1 WAALZLLYFVFZTQ-UHFFFAOYSA-N 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 claims 1
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 230000000573 anti-seizure effect Effects 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 235000020937 fasting conditions Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002040 relaxant effect Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8216208P | 2008-07-18 | 2008-07-18 | |
| US61/082,162 | 2008-07-18 | ||
| PCT/US2009/051052 WO2010009433A1 (en) | 2008-07-18 | 2009-07-17 | Modified release formulation and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011528666A JP2011528666A (ja) | 2011-11-24 |
| JP2011528666A5 true JP2011528666A5 (https=) | 2012-08-30 |
Family
ID=41550741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518947A Pending JP2011528666A (ja) | 2008-07-18 | 2009-07-17 | 放出調節製剤及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100120906A1 (https=) |
| EP (1) | EP2318001A4 (https=) |
| JP (1) | JP2011528666A (https=) |
| KR (1) | KR20110052641A (https=) |
| CN (1) | CN102170879B (https=) |
| AU (1) | AU2009270768A1 (https=) |
| BR (1) | BRPI0916000A2 (https=) |
| CA (1) | CA2731008A1 (https=) |
| CL (1) | CL2011000109A1 (https=) |
| CO (1) | CO6351716A2 (https=) |
| EA (1) | EA201170230A1 (https=) |
| IL (1) | IL210683A0 (https=) |
| MX (1) | MX2011000636A (https=) |
| NZ (1) | NZ590885A (https=) |
| WO (1) | WO2010009433A1 (https=) |
| ZA (1) | ZA201102518B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009013613A1 (de) * | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Trockenverarbeitung von Retigabin |
| DE102009013612A1 (de) * | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung |
| US10786464B2 (en) * | 2009-11-03 | 2020-09-29 | Lupin Limited | Modified release formulation of lacosamide |
| EP2525660A4 (en) * | 2010-01-20 | 2013-08-07 | Valeant Pharmaceuticals Int | FORMULATION WITH MODIFIED RELEASE AND USE METHOD |
| EP2525788A2 (en) | 2010-01-20 | 2012-11-28 | Glaxo Group Limited | Novel retigabine composition |
| SG191309A1 (en) | 2011-01-18 | 2013-07-31 | Glaxo Group Ltd | Process for the preparation of retigabine |
| CN113061089A (zh) | 2015-09-23 | 2021-07-02 | 凯瑞康宁生物工程（武汉）有限公司 | γ-羟基丁酸的前药及其组合物和用途 |
| MA43532A (fr) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals Inc | Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques |
| CA3162907A1 (en) * | 2019-12-02 | 2021-06-10 | Xenon Pharmaceuticals Inc. | Pediatric immediate-release formulation of the potassium channel opener ezogabine |
| CN117321031A (zh) * | 2021-03-19 | 2023-12-29 | 艾可斯外扎根股份有限公司 | Kv7通道开放剂的前药 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
| DE4200259A1 (de) * | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
| DE19539861A1 (de) * | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
| DE19701694A1 (de) * | 1997-01-20 | 1998-07-23 | Asta Medica Ag | Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung |
| JP2000086509A (ja) * | 1998-09-14 | 2000-03-28 | Taisho Yakuhin Kogyo Kk | ソファルコン含有製剤の製造方法 |
| US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
| US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
| NZ527771A (en) * | 1999-08-04 | 2005-04-29 | Icagen Inc | Methods for treating or preventing anxiety |
| US6117900A (en) * | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
| WO2001066081A2 (de) * | 2000-03-08 | 2001-09-13 | Awd.Pharma Gmbh & Co.Kg | Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung |
| US20020015730A1 (en) * | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
| TWI287984B (en) * | 2000-10-17 | 2007-10-11 | Wyeth Corp | Pharmaceutical composition for modulating bladder function |
| GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
| WO2002043704A1 (fr) * | 2000-12-01 | 2002-06-06 | Kyowa Hakko Kogyo Co., Ltd. | Composition a solubilite ou absorbabilite orale amelioree |
| US6589986B2 (en) * | 2000-12-20 | 2003-07-08 | Wyeth | Methods of treating anxiety disorders |
| AR033095A1 (es) * | 2001-04-04 | 2003-12-03 | Wyeth Corp | Metodos para el tratamiento de motilidad gastrica hiperactiva |
| AR033711A1 (es) * | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
| KR100425226B1 (ko) * | 2001-07-03 | 2004-03-30 | 주식회사 팜트리 | 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법 |
| GB0120835D0 (en) * | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
| SE0103369D0 (sv) * | 2001-10-09 | 2001-10-09 | Astrazeneca Ab | Pharmaceutical formulation |
| GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| AU2003260336C1 (en) * | 2002-07-29 | 2008-05-29 | Glaxo Group Limited | Sustained release formulations comprising lamotrigine |
| DE60324609D1 (de) * | 2002-09-17 | 2008-12-18 | Wyeth Corp | GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779 |
| JP2004131393A (ja) * | 2002-10-08 | 2004-04-30 | Kowa Co | 易溶出性製剤 |
| ES2222831B2 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+. |
| GB0318824D0 (en) * | 2003-08-11 | 2003-09-10 | Glaxo Group Ltd | Novel composition |
| JP2007506775A (ja) * | 2003-09-26 | 2007-03-22 | アルザ・コーポレーシヨン | 漸増する放出速度を表す制御放出製剤 |
| GB0324574D0 (en) * | 2003-10-21 | 2003-11-26 | Glaxo Group Ltd | Novel compositions |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| US20080020041A1 (en) * | 2004-10-19 | 2008-01-24 | Ayres James W | Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid |
| GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
| US20100285123A1 (en) * | 2005-06-20 | 2010-11-11 | Rudresha Korlakunte Virupakshalah Prasad | Controlled Release Dosage Formulation of Duloxetine |
| EP2404604B1 (en) * | 2006-01-05 | 2019-02-06 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
| US8558470B2 (en) * | 2006-01-20 | 2013-10-15 | Point Somee Limited Liability Company | Adaptive current regulation for solid state lighting |
| USD601689S1 (en) * | 2006-05-12 | 2009-10-06 | Glaxo Group Limited | Pharmaceutical tablet |
| CA2670966A1 (en) * | 2006-11-28 | 2008-06-05 | Valeant Pharmaceuticals International | 1,4 diamino bicyclic retigabine analogues as potassium channel modulators |
-
2009
- 2009-07-17 US US12/505,409 patent/US20100120906A1/en not_active Abandoned
- 2009-07-17 KR KR1020117003868A patent/KR20110052641A/ko not_active Withdrawn
- 2009-07-17 AU AU2009270768A patent/AU2009270768A1/en not_active Abandoned
- 2009-07-17 WO PCT/US2009/051052 patent/WO2010009433A1/en not_active Ceased
- 2009-07-17 NZ NZ590885A patent/NZ590885A/xx not_active IP Right Cessation
- 2009-07-17 EP EP09798829A patent/EP2318001A4/en not_active Withdrawn
- 2009-07-17 BR BRPI0916000A patent/BRPI0916000A2/pt not_active IP Right Cessation
- 2009-07-17 CN CN200980136417.8A patent/CN102170879B/zh not_active Expired - Fee Related
- 2009-07-17 EA EA201170230A patent/EA201170230A1/ru unknown
- 2009-07-17 MX MX2011000636A patent/MX2011000636A/es not_active Application Discontinuation
- 2009-07-17 JP JP2011518947A patent/JP2011528666A/ja active Pending
- 2009-07-17 CA CA2731008A patent/CA2731008A1/en not_active Abandoned
-
2011
- 2011-01-16 IL IL210683A patent/IL210683A0/en unknown
- 2011-01-18 CL CL2011000109A patent/CL2011000109A1/es unknown
- 2011-02-17 CO CO11018953A patent/CO6351716A2/es not_active Application Discontinuation
- 2011-04-05 ZA ZA2011/02518A patent/ZA201102518B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528666A5 (https=) | ||
| CA2787907A1 (en) | Modified release formulation and methods of use | |
| CA2794171C (en) | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances | |
| JP2019514855A5 (https=) | ||
| JP2017222705A5 (https=) | ||
| JP2015506377A5 (https=) | ||
| JP2011504491A (ja) | プレガバリンの制御放出医薬組成物 | |
| JP2019513800A (ja) | メサラジンの経口薬学的組成物 | |
| AU2015349896A1 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| US20070122480A1 (en) | Sustained release formulations | |
| US20110123575A1 (en) | Modified release niacin formulations | |
| US9820936B2 (en) | Oral controlled release pharmaceutical compositions of Bepotastine | |
| KR20070069105A (ko) | 서방성 제제 | |
| RU2738114C2 (ru) | Пероральные фармацевтические композиции никотинамида | |
| US20090028944A1 (en) | Pharmaceutical compositions comprising mesalamine | |
| AU2016231883B2 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| US20140010883A1 (en) | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| US20110217373A1 (en) | Extended release pharmaceutical compositions of guanfacine hydrochloride | |
| WO2020101586A1 (en) | Controlled release propiverine formulations | |
| US20200054659A1 (en) | Extended release capecitabine capsules | |
| JPWO2022181625A5 (https=) | ||
| US20070292505A1 (en) | Controlled release alfuzosin hydrochloride formulation | |
| JPWO2023158616A5 (https=) | ||
| WO2025212071A1 (en) | A solid dispersion of enzalutamide |